Vafidemstat (ORY-2001) (ORY-2001) 是一种口服、脑渗透性、双赖氨酸特异性组蛋白去甲基化酶 (LSD1)/MAO-B 抑制剂。
Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].
[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.
动态评分
0.0